Halozyme Therapeutics (HALO) 7.99 $HALO
Biotech Equities Update - Biogen Idec, ACADIA Pharma, Halozyme Therapeutics, Neurocrine Biosciences, and Bluebird Bio
PR Newswire - Fri Dec 12, 7:50AM CST
Investor-Edge has initiated coverage on the following equities: Biogen Idec Inc. (NASDAQ: BIIB), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Halozyme Therapeutics Inc. (NASDAQ: HALO), Neurocrine Biosciences Inc. (NASDAQ: NBIX), and Bluebird Bio Inc. (NASDAQ: BLUE). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Thursday, December 11, 2014, the NASDAQ Composite ended at 4,708.16, up 0.52%, the Dow Jones Industrial Average advanced 0.36%, to finish the day at 17,596.34, and the S&P 500 closed at 2,035.33, up 0.45%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 806.11, up 0.26%, with the index also advancing 8.67% in the previous three months. Register for your complimentary reports on these five stocks at:
BLUE: 91.28 (+5.16), BIIB: 344.49 (+2.16), ACAD: 32.53 (-0.10), NBIX: 21.97 (+0.12), HALO: 7.99 (-0.16)
Halozyme Announces Presentations Of Preclinical Data At The San Antonio Breast Cancer Symposium Annual Meeting
PR Newswire - Fri Dec 12, 7:00AM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced that two scientific poster presentations on the pharmacology of PEGPH20 will be made at the 37th Annual San Antonio Breast Cancer Symposium (SABCS) today. The first of the presentations includes preclinical data showing that treatment of tumors with PEGPH20 enhances the action of immune-based cancer therapy such as monoclonal antibodies (mAbs). The second presentation includes additional supportive preclinical information on the utility of hyaluronan (HA) as a potential biomarker for cancer treatments. PEGPH20 is an investigational PEGylated form of rHuPH20 under development by Halozyme. PEGPH20 degrades the hyaluronan coating that may provide a supportive environment in many solid tumors.
HALO: 7.99 (-0.16)
Can Pfizer’s Cholesterol Drug Catch Up To The Competition?
Leo Sun, The Motley Fool - Motley Fool - Thu Dec 11, 6:28AM CST
Pfizer 's revenue has dramatically declined since 2011, the year Lipitor went off patent in the U.S. The blockbuster cholesterol drug, which already lost exclusivity in several markets at the time, still generated sales of $9.6 billion that year,...
HALO: 7.99 (-0.16), PFE: 30.95 (-0.70), AMGN: 164.53 (-1.55), SNY: 45.16 (-1.05), REGN: 416.44 (-7.91)
Halozyme Therapeutics - Buy The Drug Delivery Platform And Get A Cancer Drug For Free
Small Pharma Analyst - at Seeking Alpha - Tue Dec 09, 10:56AM CST
HALO: 7.99 (-0.16)
Halozyme Therapeutics To Present At The 25th Annual Oppenheimer Healthcare Conference
PR Newswire - Wed Dec 03, 3:15PM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the 25th Annual Oppenheimer Healthcare Conference in New York on Wednesday, December 10, 2014 at 1:00 p.m. ET/10:00 a.m. PT. David Ramsay, Vice President and Chief Financial Officer, will provide a corporate overview.
HALO: 7.99 (-0.16)
Halozyme Therapeutics To Present At The Piper Jaffray Healthcare Conference
PR Newswire - Tue Nov 25, 3:15PM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the Piper Jaffray Healthcare Conference in New York on Wednesday, December 3, 2014 at 1:00 p.m. EDT/10:00 a.m. PDT. Dr. Helen Torley, President and Chief Executive Officer, will provide a corporate overview.
HALO: 7.99 (-0.16)
Halozyme Therapeutics Earnings Review: 14 Days after Announcement Shares Down 8.6% (HALO)
Comtex SmarTrend(R) - Mon Nov 24, 9:18AM CST
When Halozyme Therapeutics (NASDAQ:HALO) reported earnings 14 days ago on November 10th, 2014, analysts, on average, expected the company to report a loss of $0.14 on sales of $16.5 million. Halozyme Therapeutics actually reported a loss of $0.16 per share on sales of $14.6 million, missing EPS estimates by $0.02 and missing revenue estimates by $1.9 million. Since the company's report, shares of Halozyme Therapeutics have fallen from $9.32 to $8.52, representing a loss of 8.6% in the past 14 days.
HALO: 7.99 (-0.16)
Halozyme Therapeutics Earnings Review: 7 Days after Announcement Shares Down 8.4% (HALO)
Comtex SmarTrend(R) - Mon Nov 17, 3:10PM CST
A week ago on November 10th, 2014 Halozyme Therapeutics (NASDAQ:HALO) reported earnings and analysts, on average, expected a loss of $0.14 on sales of $16.5 million. The company actually reported a loss of $0.16 per share on sales of $14.6 million, missing EPS estimates by $0.02 and missing revenue estimates by $1.9 million. Since the company's report, shares of Halozyme Therapeutics have fallen from $9.32 to $8.54, representing a loss of 8.4% in the past 7 days.
HALO: 7.99 (-0.16)
Halozyme Therapeutics (HALO) Stock Is Slipping Today on Weak Third Quarter Earnings
at The Street - Tue Nov 11, 10:42AM CST
Halozyme Therapeutics (HALO) stock is down after the company reported lower than expected third quarter earnings late Monday.
HALO: 7.99 (-0.16)
Halozyme net loss worsens in Q3
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 7:55AM CST
HALO: 7.99 (-0.16)
Halozyme Therapeutics' (HALO) CEO Helen Torley on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 10, 8:33PM CST
HALO: 7.99 (-0.16)
Halozyme Therapeutics meets 3Q profit forecasts
Automated Insights - Mon Nov 10, 5:51PM CST
SAN DIEGO (AP) _ Halozyme Therapeutics Inc. (HALO) on Monday reported a loss of $20.3 million in its third quarter.
HALO: 7.99 (-0.16)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 4:36PM CST
DTSI: 30.87 (-0.20), W: 18.44 (-0.94), HALO: 7.99 (-0.16), MODN: 10.50 (+0.05), CALL: 7.70 (-0.05), LLNW: 2.86 (+0.01), KRG: 27.78 (unch), VSLR: 8.08 (+0.08), CMLS: 3.87 (+0.03), SSE: 4.58 (-0.12)
Halozyme Therapeutics misses by $0.02, misses on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 3:21PM CST
HALO: 7.99 (-0.16)
Halozyme Reports Third Quarter 2014 Financial Results
PR Newswire - Mon Nov 10, 3:05PM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the third quarter ended September 30, 2014. Financial highlights for the third quarter include revenues of $14.6 million and a net loss of $20.3 million, or $0.16 per share. This compares to revenues of $16.0 million and a net loss of $19.3 million, or $0.17 per share, for the third quarter of 2013.
HALO: 7.99 (-0.16)
Notable earnings after Monday’s close
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 4:35PM CST
HK: 2.01 (-0.09), WWD: 48.04 (-1.66), LLNW: 2.86 (+0.01), FXEN: 1.60 (-0.07), RMTI: 8.20 (+0.04), CZR: 12.83 (-2.03), EGY: 4.49 (-0.06), ICUI: 80.95 (-1.04), ICEL: 5.19 (-0.28), SAAS: 8.09 (-0.14), DMD: 6.35 (+0.09), NPSP: 31.28 (-0.99), SCLN: 8.23 (-0.32), ATHX: 1.36 (+0.05), CMLS: 3.87 (+0.03), TC: 1.38 (-0.07), ATW: 27.19 (-0.52), CLUB: 6.22 (+0.01), RAX: 45.39 (-0.86), PTLA: 28.27 (-0.27), IPAR: 26.05 (-0.73), ATLS: 26.31 (-0.13), AMBC: 23.08 (-0.97), CUI: 7.37 (-0.12), PDLI: 7.41 (-0.08), OMER: 22.81 (+0.12), PRAA: 57.23 (-0.17), CARA: 9.94 (-0.06), HALO: 7.99 (-0.16), MODN: 10.50 (+0.05), CALL: 7.70 (-0.05), ASEI: 47.24 (-1.33), HGR: 21.22 (+0.21), ERII: 4.72 (+0.06)
Halozyme Therapeutics To Present At The Credit Suisse Healthcare Conference
PR Newswire - Wed Nov 05, 3:15PM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the Credit Suisse Healthcare Conference in Scottsdale, Arizona on Wednesday, November 12, 2014 at 4:00 p.m. ET/2:00 p.m. MT/1:00 p.m. PT. Dr. Helen Torley, President and Chief Executive Officer, will provide a corporate overview.
HALO: 7.99 (-0.16)
Halozyme to Host Third Quarter 2014 Financial Results Conference Call
PR Newswire - Mon Nov 03, 3:15PM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the third quarter 2014 on Monday, November 10, 2014 at 4:30 p.m. ET/1:30 p.m. PT. Dr. Helen Torley, President and Chief Executive Officer, will lead the call. On the same date post-market, Halozyme will release financial results for the third quarter 2014.
HALO: 7.99 (-0.16)
Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma
PR Newswire - Fri Oct 31, 7:40AM CDT
Investor-Edge has initiated coverage on the following equities: Nanosphere Inc. (NASDAQ: NSPH), Isis Pharmaceuticals Inc. (NASDAQ: ISIS), Halozyme Therapeutics Inc. (NASDAQ: HALO), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), and Synta Pharmaceuticals Corporation (NASDAQ: SNTA). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Thursday, October 30, 2014, the NASDAQ Composite ended at 4,566.14, up 0.37%, the Dow Jones Industrial Average advanced 1.30%, to finish the day at 17,195.42, and the S&P 500 closed at 1,994.65, up 0.62%. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 774.91, up 1.81%, with the index also advancing 7.78% in the previous three months. Register for your complimentary reports on these five stocks at:
SNTA: 2.87 (+0.04), ACAD: 32.53 (-0.10), HALO: 7.99 (-0.16), ISIS: 62.32 (+0.45), NSPH: 0.36 (+0.02)
NewLink Genetics Corporation (NLNK) in Focus: Stock Soars 15.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Oct 23, 8:18AM CDT
NewLink Genetics Corporation (NLNK) was a big mover last session, as the company saw its shares rise by over 15% on the day.
HALO: 7.99 (-0.16), NLNK: 35.69 (+0.27), ILMN: 184.30 (-2.53), EXAS: 27.96 (-0.24)
Biotech Equities Update - Biogen Idec, ACADIA Pharma, Halozyme Therapeutics, Neurocrine Biosciences, and Bluebird Bio
PR Newswire - Fri Dec 12, 7:50AM CST
Investor-Edge has initiated coverage on the following equities: Biogen Idec Inc. (NASDAQ: BIIB), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), Halozyme Therapeutics Inc. (NASDAQ: HALO), Neurocrine Biosciences Inc. (NASDAQ: NBIX), and Bluebird Bio Inc. (NASDAQ: BLUE). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Thursday, December 11, 2014, the NASDAQ Composite ended at 4,708.16, up 0.52%, the Dow Jones Industrial Average advanced 0.36%, to finish the day at 17,596.34, and the S&P 500 closed at 2,035.33, up 0.45%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 806.11, up 0.26%, with the index also advancing 8.67% in the previous three months. Register for your complimentary reports on these five stocks at:
BLUE: 91.28 (+5.16), BIIB: 344.49 (+2.16), ACAD: 32.53 (-0.10), NBIX: 21.97 (+0.12), HALO: 7.99 (-0.16)
Halozyme Announces Presentations Of Preclinical Data At The San Antonio Breast Cancer Symposium Annual Meeting
PR Newswire - Fri Dec 12, 7:00AM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced that two scientific poster presentations on the pharmacology of PEGPH20 will be made at the 37th Annual San Antonio Breast Cancer Symposium (SABCS) today. The first of the presentations includes preclinical data showing that treatment of tumors with PEGPH20 enhances the action of immune-based cancer therapy such as monoclonal antibodies (mAbs). The second presentation includes additional supportive preclinical information on the utility of hyaluronan (HA) as a potential biomarker for cancer treatments. PEGPH20 is an investigational PEGylated form of rHuPH20 under development by Halozyme. PEGPH20 degrades the hyaluronan coating that may provide a supportive environment in many solid tumors.
HALO: 7.99 (-0.16)
Can Pfizer’s Cholesterol Drug Catch Up To The Competition?
Leo Sun, The Motley Fool - Motley Fool - Thu Dec 11, 6:28AM CST
Pfizer 's revenue has dramatically declined since 2011, the year Lipitor went off patent in the U.S. The blockbuster cholesterol drug, which already lost exclusivity in several markets at the time, still generated sales of $9.6 billion that year,...
HALO: 7.99 (-0.16), PFE: 30.95 (-0.70), AMGN: 164.53 (-1.55), SNY: 45.16 (-1.05), REGN: 416.44 (-7.91)
Halozyme Therapeutics - Buy The Drug Delivery Platform And Get A Cancer Drug For Free
Small Pharma Analyst - at Seeking Alpha - Tue Dec 09, 10:56AM CST
HALO: 7.99 (-0.16)
Halozyme Therapeutics To Present At The 25th Annual Oppenheimer Healthcare Conference
PR Newswire - Wed Dec 03, 3:15PM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the 25th Annual Oppenheimer Healthcare Conference in New York on Wednesday, December 10, 2014 at 1:00 p.m. ET/10:00 a.m. PT. David Ramsay, Vice President and Chief Financial Officer, will provide a corporate overview.
HALO: 7.99 (-0.16)
Halozyme Therapeutics To Present At The Piper Jaffray Healthcare Conference
PR Newswire - Tue Nov 25, 3:15PM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the Piper Jaffray Healthcare Conference in New York on Wednesday, December 3, 2014 at 1:00 p.m. EDT/10:00 a.m. PDT. Dr. Helen Torley, President and Chief Executive Officer, will provide a corporate overview.
HALO: 7.99 (-0.16)
Halozyme Therapeutics Earnings Review: 14 Days after Announcement Shares Down 8.6% (HALO)
Comtex SmarTrend(R) - Mon Nov 24, 9:18AM CST
When Halozyme Therapeutics (NASDAQ:HALO) reported earnings 14 days ago on November 10th, 2014, analysts, on average, expected the company to report a loss of $0.14 on sales of $16.5 million. Halozyme Therapeutics actually reported a loss of $0.16 per share on sales of $14.6 million, missing EPS estimates by $0.02 and missing revenue estimates by $1.9 million. Since the company's report, shares of Halozyme Therapeutics have fallen from $9.32 to $8.52, representing a loss of 8.6% in the past 14 days.
HALO: 7.99 (-0.16)
Halozyme Therapeutics Earnings Review: 7 Days after Announcement Shares Down 8.4% (HALO)
Comtex SmarTrend(R) - Mon Nov 17, 3:10PM CST
A week ago on November 10th, 2014 Halozyme Therapeutics (NASDAQ:HALO) reported earnings and analysts, on average, expected a loss of $0.14 on sales of $16.5 million. The company actually reported a loss of $0.16 per share on sales of $14.6 million, missing EPS estimates by $0.02 and missing revenue estimates by $1.9 million. Since the company's report, shares of Halozyme Therapeutics have fallen from $9.32 to $8.54, representing a loss of 8.4% in the past 7 days.
HALO: 7.99 (-0.16)
Halozyme Therapeutics (HALO) Stock Is Slipping Today on Weak Third Quarter Earnings
at The Street - Tue Nov 11, 10:42AM CST
Halozyme Therapeutics (HALO) stock is down after the company reported lower than expected third quarter earnings late Monday.
HALO: 7.99 (-0.16)
Halozyme net loss worsens in Q3
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 7:55AM CST
HALO: 7.99 (-0.16)
Halozyme Therapeutics' (HALO) CEO Helen Torley on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 10, 8:33PM CST
HALO: 7.99 (-0.16)
Halozyme Therapeutics meets 3Q profit forecasts
Automated Insights - Mon Nov 10, 5:51PM CST
SAN DIEGO (AP) _ Halozyme Therapeutics Inc. (HALO) on Monday reported a loss of $20.3 million in its third quarter.
HALO: 7.99 (-0.16)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 4:36PM CST
DTSI: 30.87 (-0.20), W: 18.44 (-0.94), HALO: 7.99 (-0.16), MODN: 10.50 (+0.05), CALL: 7.70 (-0.05), LLNW: 2.86 (+0.01), KRG: 27.78 (unch), VSLR: 8.08 (+0.08), CMLS: 3.87 (+0.03), SSE: 4.58 (-0.12)
Halozyme Therapeutics misses by $0.02, misses on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 3:21PM CST
HALO: 7.99 (-0.16)
Halozyme Reports Third Quarter 2014 Financial Results
PR Newswire - Mon Nov 10, 3:05PM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today reported financial results for the third quarter ended September 30, 2014. Financial highlights for the third quarter include revenues of $14.6 million and a net loss of $20.3 million, or $0.16 per share. This compares to revenues of $16.0 million and a net loss of $19.3 million, or $0.17 per share, for the third quarter of 2013.
HALO: 7.99 (-0.16)
Notable earnings after Monday’s close
Seeking Alpha - at Seeking Alpha - Sun Nov 09, 4:35PM CST
HK: 2.01 (-0.09), WWD: 48.04 (-1.66), LLNW: 2.86 (+0.01), FXEN: 1.60 (-0.07), RMTI: 8.20 (+0.04), CZR: 12.83 (-2.03), EGY: 4.49 (-0.06), ICUI: 80.95 (-1.04), ICEL: 5.19 (-0.28), SAAS: 8.09 (-0.14), DMD: 6.35 (+0.09), NPSP: 31.28 (-0.99), SCLN: 8.23 (-0.32), ATHX: 1.36 (+0.05), CMLS: 3.87 (+0.03), TC: 1.38 (-0.07), ATW: 27.19 (-0.52), CLUB: 6.22 (+0.01), RAX: 45.39 (-0.86), PTLA: 28.27 (-0.27), IPAR: 26.05 (-0.73), ATLS: 26.31 (-0.13), AMBC: 23.08 (-0.97), CUI: 7.37 (-0.12), PDLI: 7.41 (-0.08), OMER: 22.81 (+0.12), PRAA: 57.23 (-0.17), CARA: 9.94 (-0.06), HALO: 7.99 (-0.16), MODN: 10.50 (+0.05), CALL: 7.70 (-0.05), ASEI: 47.24 (-1.33), HGR: 21.22 (+0.21), ERII: 4.72 (+0.06)
Halozyme Therapeutics To Present At The Credit Suisse Healthcare Conference
PR Newswire - Wed Nov 05, 3:15PM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the Credit Suisse Healthcare Conference in Scottsdale, Arizona on Wednesday, November 12, 2014 at 4:00 p.m. ET/2:00 p.m. MT/1:00 p.m. PT. Dr. Helen Torley, President and Chief Executive Officer, will provide a corporate overview.
HALO: 7.99 (-0.16)
Halozyme to Host Third Quarter 2014 Financial Results Conference Call
PR Newswire - Mon Nov 03, 3:15PM CST
Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the third quarter 2014 on Monday, November 10, 2014 at 4:30 p.m. ET/1:30 p.m. PT. Dr. Helen Torley, President and Chief Executive Officer, will lead the call. On the same date post-market, Halozyme will release financial results for the third quarter 2014.
HALO: 7.99 (-0.16)
Momentum Indicators for Biotech Stocks -- Nanosphere, Isis Pharma, Halozyme Therapeutics, ACADIA Pharma, and Synta Pharma
PR Newswire - Fri Oct 31, 7:40AM CDT
Investor-Edge has initiated coverage on the following equities: Nanosphere Inc. (NASDAQ: NSPH), Isis Pharmaceuticals Inc. (NASDAQ: ISIS), Halozyme Therapeutics Inc. (NASDAQ: HALO), ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), and Synta Pharmaceuticals Corporation (NASDAQ: SNTA). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Thursday, October 30, 2014, the NASDAQ Composite ended at 4,566.14, up 0.37%, the Dow Jones Industrial Average advanced 1.30%, to finish the day at 17,195.42, and the S&P 500 closed at 1,994.65, up 0.62%. The gains were broad based as nine out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 774.91, up 1.81%, with the index also advancing 7.78% in the previous three months. Register for your complimentary reports on these five stocks at:
SNTA: 2.87 (+0.04), ACAD: 32.53 (-0.10), HALO: 7.99 (-0.16), ISIS: 62.32 (+0.45), NSPH: 0.36 (+0.02)
NewLink Genetics Corporation (NLNK) in Focus: Stock Soars 15.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Oct 23, 8:18AM CDT
NewLink Genetics Corporation (NLNK) was a big mover last session, as the company saw its shares rise by over 15% on the day.
HALO: 7.99 (-0.16), NLNK: 35.69 (+0.27), ILMN: 184.30 (-2.53), EXAS: 27.96 (-0.24)
